Pediatrix Medical Group, Inc. — Medical Care Facilities. Scored on the same transparent 7-signal model behind the daily rankings.
★
MD
Pediatrix Medical Group, Inc. · Medical Care Facilities
FCF$237mC
Rev-4.9%D+
D/E0.72C+
P/E13.0xA
PEG0.24A
61.1Score
$26.92$2.2B
1Y Target$23.17Analyst consensus · 6 analysts
5Y Target$29.25Compound horizon
10Y Target$37.51Long-dated conviction
FCF$237mTTM · 03/26C
FCF $237m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev-4.9%TTM YoYD+
Revenue -4.9% — shrinking; needs a catalyst to reverse
D/E0.72C+
D/E 0.72 — above the Healthcare debt median (≈75th pctile)
P/E13.0xA
P/E 13.0 — cheapest decile in Healthcare (≈10th pctile)
PEG0.24A
PEG 0.24 — exceptional; paying well under fair value for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 61.1
Quality0.61
Growth0.44
Value0.84
Why this score
Buying back stock
Entry · Margin of safety
52-week rangeNear 52-week high
4% off the 12-month high
vs DCF fair value54% belowest. fair value ~$59
Quality signals · context only
ROIC6.7% · C+return on invested capital — not score-weighted
Why now
Medical Care Facilities · market cap $2.2b. 4% off the 52-week high of $27.94. PEG 0.24 — paying under fair value for the growth rate. 6 sell-side analysts publish a mean 1-yr target of $23.17 (implying -14% upside).
Moat
ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 136% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon
1-3 yr $23.17 (6-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $29.25 at ~2% CAGR — dividend + buyback compounding. 10 yr $37.51 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · MD
$
%
%
Shares to buy
74
Position size
$1,992
4.0% of portfolio
Stop price
$20.19
25% below $26.92
$ at risk if stopped
$498.02
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Pediatrix Medical Group, Inc. (MD): score, valuation & FAQ
Pediatrix Medical Group, Inc. (MD) is a Medical Care Facilities company that scores 61.1 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A) and PEG (A), while Rev (D+) rate weaker. On valuation, MD sits about 54% below our discounted-cash-flow fair value (a margin of safety).
Is MD a good stock to buy?
Bull Rankings scores MD 61.1 out of 100 on its quality-growth model, which is a middling reading. That is driven by P/E (A) and PEG (A). A score is a quantitative screen of Pediatrix Medical Group, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does MD score 61.1 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). MD earns its highest marks on P/E (A) and PEG (A), and is held back by Rev (D+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is MD overvalued or undervalued?
Based on $26.92, MD sits about 54% below our discounted-cash-flow fair value (a margin of safety). It trades at a 13.0x× P/E (graded A). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in MD?
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.